menu
    • menu
    [{"orgOrder":0,"company":"Q BioMed","sponsor":"Clionix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Licensing Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q BioMed \/ Clionix","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Clionix"},{"orgOrder":0,"company":"Q BioMed","sponsor":"isoSolutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q BioMed \/ isoSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ isoSolutions"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q BioMed \/ Chengdu Syncor Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Chengdu Syncor Pharmaceutical"},{"orgOrder":0,"company":"X-pert Med GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Strontium-89 Chloride","moa":"Bone resorption","graph1":"Dermatology","graph2":"Phase I","graph3":"X-pert Med GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X-pert Med GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"X-pert Med GmbH \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Strontium-89 Chloride

    Menu

    Strontium-89 Chloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Q BioMed

                            U.S.A arrow
                            AusBiotech
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            AusBiotech
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Chengdu Syncor Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market

                            Details : The agreement is expected to be a high-growth opportunity to supply Strontium89 in the Chinese market. Strontium89 is FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic...

                            Product Name : Metastron

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            March 07, 2022

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Chengdu Syncor Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Q BioMed

                            U.S.A arrow
                            AusBiotech
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            AusBiotech
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : isoSolutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

                            Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.

                            Product Name : Metastron

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            August 10, 2021

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : isoSolutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Q BioMed

                            U.S.A arrow
                            AusBiotech
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            AusBiotech
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Clionix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Midd...

                            Details : Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.

                            Product Name : Metastron

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            July 12, 2021

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Clionix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            X-pert Med GmbH

                            Country arrow
                            AusBiotech
                            Not Confirmed

                            X-pert Med GmbH

                            Country arrow
                            AusBiotech
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ultra Violet B Radiation (UVR) Study of Strontium Chloride Hexahydrate Hydrocortisone

                            Details : Strontium Chloride Hexahydrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Erythema.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 23, 2011

                            Lead Product(s) : Strontium-89 Chloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth